Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Merck Vs. AbbVie: Which Is Better Buy As The Patent Cliffs Approach?

2022-11-22
I will be comparing AbbVie and Merck to see which is better positioned for its patent cliff. Read to know why I like AbbVie more than Merck.

Institutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term losses

2022-11-17
To get a sense of who is truly in control of Seagen Inc. ( NASDAQ:SGEN ), it is important to understand the ownership...

Did You Buy And Not Sell Friday? You're Doing It Wrong - Again

2022-11-14
This week saw quite a bit of volatility yet the VIX continues to fall. Read more to see why I expect this week we will see quite a comedown.

Seagen (SGEN) Receives a Buy from SVB Securities

2022-11-13
SVB Securities analyst Andrew Berens reiterated a Buy rating on Seagen (SGEN – Research Report) on November 10 and set a price target of $112.00. The company&...

Seagen names new CEO following May resignation of Clay Siegall

2022-11-11
David Epstein spent more than 25 years at the Swiss pharmaceutical giant Novartis, where he helped build its oncology business.

Society for Immunotherapy of Cancer to hold a meeting

2022-11-11
37th Annual Meeting SITC ... ABMD, ADPT, ALKS, AMGN, ASND, BMY, CGEN, CLRB, CRL, INKT, INCY, PHIO, INBX, XNCR, VCYT, TXG, TPST, TMO, TIL, SGEN, REGN, REPL, RHHBY, DNA, CUE, IOVA, IPSC, LH, MRK, MXCT, EXEL, FATE, GMAB

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

2022-11-10
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. The approval is based on data from a phase 3 study (AHOD1331) conducted by the Children's Oncology Group (COG

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

2022-11-10
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 8-12 in Boston. The presentations highlight data from multiple ongoing clinical and preclinical research studies that employ Seagen’s proprietary antibody-drug conjugate (ADC) technology, as well as other novel cancer targeting appro

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

2022-11-10
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company’s Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American

Seagen Names David R. Epstein as Chief Executive Officer and Director

2022-11-10
BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novarti